Familial Dysautonomia Withdrawn Phase 2 Trials for Dronabinol (DB00470)

Also known as: Riley-Day syndrome / Dysautonomia, Familial / Familial dysautonomia [Riley-Day] / HSAN III

IndicationStatusPhase
DBCOND0048634 (Familial Dysautonomia)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02608931The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial DysautonomiaTreatment